| |
| Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis |
| Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K |
|
|
| |
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Applied Health Economics and Health Policy 2009; 7(2): 91-108 Indexing Status Subject indexing assigned by NLM MeSH Adult; Antibodies, Monoclonal /adverse effects /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; Female; Glatiramer Acetate; Humans; Immunosuppressive Agents /adverse effects /economics /therapeutic use; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting /drug therapy /economics; Natalizumab; Peptides /adverse effects /economics /therapeutic use AccessionNumber 22009103306 Date bibliographic record published 02/06/2010 |
| |
|
|
